recogn
virus
particular
emphasi
one
might
amen
therapi
tom
fever
may
absent
lung
transplant
recipi
exampl
may
initi
subject
symptom
short
ness
breath
subtl
chang
pulmonari
function
test
without
typic
symptom
viral
shed
usual
prolong
among
transplant
recipi
prolong
shed
seen
even
use
antivir
therefor
may
contribut
increas
risk
resist
variant
emerg
transplant
recipi
higher
risk
infecti
complica
tion
compar
immunocompet
host
respiratori
viral
infect
signific
risk
factor
subsequ
develop
ment
fungal
bacteri
pneumonia
respiratori
viral
infect
appear
risk
factor
acut
chronic
reject
greatest
risk
lung
tran
plant
recipi
although
data
topic
litera
ture
conflict
pathogenesi
link
respiratori
viral
infect
reject
clearli
understood
wide
rang
pcrbase
assay
detect
respiratori
virus
commerci
avail
mani
center
local
develop
assay
detect
select
virus
nucleic
acid
amplif
assay
appear
sensit
diagnost
tool
avail
allow
simultan
detect
broad
rang
respiratori
pathogen
singl
sampl
therefor
prefer
diagnost
test
method
immunocompromis
patient
multiplex
pcr
assay
provid
advantag
identif
virus
routin
found
convent
method
includ
rhinoviru
hmpv
although
multiplex
affect
sen
sitiv
assay
commerci
avail
multiplex
assay
differ
sensit
specif
differ
virus
notabl
ade
noviru
clinician
awar
perform
characterist
assay
use
influenza
pcr
assay
di
tinguish
among
viral
subtyp
quantifi
viral
load
although
avail
center
rapid
pcrbase
assay
allow
rapid
sult
within
hour
particularli
influenza
rsv
although
sensit
may
vari
among
viru
type
rapid
antigen
detect
avail
influenza
rsv
advantag
rapid
result
test
within
suboptim
sensit
low
predict
valu
sever
studi
direct
fluoresc
antibodi
dfa
test
primari
patient
specimen
document
sensit
approach
pcr
certain
virus
patient
known
suspect
influenza
isol
patient
standard
droplet
precaut
influenza
vaccin
key
measur
prevent
influenza
patient
influenza
infect
healthcar
set
need
isol
standard
droplet
measur
strong
moder
inactiv
influenza
vaccin
administ
sot
recipi
household
member
strong
high
patient
influenza
vaccin
contraind
may
insuffici
respons
eg
therapi
acut
reject
earli
transplant
antivir
prophylaxi
oseltamivir
mg
daili
durat
week
renal
adjust
need
start
begin
influenza
season
may
propos
weak
high
sot
recipi
close
contact
patient
docu
ment
influenza
particular
case
nosocomi
influenza
patient
enhanc
immunosuppress
suggest
admin
ister
postexposur
prophylaxi
oseltamivir
strong
low
two
famili
drug
approv
treatment
influenza
name
inhibitor
neuraminidas
inhibitor
inhibitor
amantadin
rimantadin
activ
influenza
b
high
incid
antivir
resist
influenza
drug
longer
recommend
treatment
influenza
neuraminidas
inhibitor
includ
oral
os
eltamivir
inhal
zanamivir
intraven
peramivir
tabl
laninamivir
longact
inhal
neuraminidas
inhibitor
approv
japan
prophylaxi
treatment
influenza
consid
case
lifethreaten
infect
concern
oral
absorpt
although
mention
experi
drug
sot
recipi
lack
use
amantadin
rimantadin
treatment
influ
enza
longer
recommend
due
high
rate
resist
drug
rate
oseltamivir
resist
high
prepandem
influenza
viru
antivir
resist
occasion
describ
new
influenza
strain
immunosuppress
exposur
oseltamivir
risk
factor
develop
antivir
resist
resist
virus
patient
expos
oseltamivir
caus
mutat
result
increas
peramivir
retain
zanamivir
activ
transplant
recipi
receiv
antivir
therapi
neur
aminidas
inhibitor
either
oseltamivir
inhal
zanamivir
influenza
suspect
strong
moder
although
earli
hour
administr
antivir
associ
ate
better
outcom
symptomat
patient
ceiv
antivir
therapi
irrespect
durat
symptom
onset
strong
low
durat
antivir
therapi
least
day
antivir
therapi
may
prolong
case
persist
clinic
symptom
weak
low
doubl
dose
oseltamivir
may
consid
sever
case
case
insuffici
respons
therapi
weak
low
iv
drug
peramivir
zanamivir
also
use
select
case
intub
patient
concern
oral
absorpt
weak
low
resist
test
consid
clinic
symptom
andor
viral
shed
present
despit
antivir
therapi
rsv
paramyxoviru
genu
pneumoviru
caus
sea
sonal
annual
epidem
worldwid
yearround
diseas
seen
tropic
locat
patient
known
suspect
rsv
isol
patient
use
standard
contact
precaut
prophylaxi
rsvspecif
human
monoclon
antibodi
palivizumab
shown
effect
highrisk
infant
children
month
specif
underli
condit
updat
recommenda
tion
regard
use
publish
american
academi
pediatr
specif
recommend
given
immunocompromis
individu
except
children
younger
month
profoundli
immunocompromis
rsv
season
may
consid
prophylaxi
survey
data
suggest
antibodybas
prophylaxi
commonli
use
among
pediatr
transplant
center
howev
studi
conduct
evalu
use
solid
organ
transplant
set
cost
adult
signific
approv
vaccin
prevent
rsv
although
variou
vaccin
formul
develop
ribavirin
nucleosid
analog
activ
rsv
aero
although
respiratori
virus
associ
creas
risk
progress
oblit
bronchiol
lung
tran
plant
recipi
associ
appear
clearest
strongest
piv
lower
tract
diseas
patient
known
suspect
piv
isol
patient
use
standard
contact
precaut
ap
prove
vaccin
recogn
prevent
antivir
agent
although
use
ivig
ribavirin
associ
ben
efit
manag
piv
infect
stem
cell
transplant
cipient
ribavirin
vitro
activ
inhal
form
use
treat
lung
transplant
recipi
lower
tract
diseas
expert
also
consid
use
ivig
corticosteroid
well
inhal
recombin
fusion
protein
undergo
investig
treatment
piv
lower
respiratori
tract
infect
treatment
lung
transplant
recipi
piv
lower
tract
infec
tion
ribavirin
consid
weak
low
adjunct
therapi
ribavirin
includ
ivig
corticosteroid
may
consid
lung
transplant
recipi
weak
low
use
molecular
diagnost
wider
rang
respiratori
virus
isol
mani
virus
newli
recogn
variant
coronaviru
polyomavi
ruse
wu
ki
virus
bocaviru
wide
studi
transplant
recipi
clinic
impact
fulli
assess
sever
sometim
fatal
case
virus
immunocompromis
patient
recogn
consid
differenti
diagnosi
patient
pre
sent
sever
lower
respiratori
tract
diseas
newli
identifi
virus
challeng
diagnos
sinc
includ
routin
clinic
avail
diagnost
test
addit
opti
mal
manag
pathogen
defin
although
respiratori
virus
increasingli
recogn
caus
morbid
mortal
transplant
recipi
still
much
learn
impact
virus
prospect
stud
i
use
molecular
diagnost
need
understand
true
epidemiolog
clinic
spectrum
respiratori
viral
diseas
particular
studi
longterm
consequ
infect
even
mild
asymptomat
need
particularli
investig
inhal
recombin
fu
sion
protein
shown
promis
inhibit
piv
replic
addit
adopt
tcell
therapi
includ
gener
piv
specif
hmpv
tcell
healthi
donor
emerg
therapeut
modal
prospect
trial
need
defin
optim
time
durat
treatment
regimen
virus
manuscript
modifi
previou
guidelin
written
